Cannabis operator MariMed Q1 revenue rises, adjusted EBITDA improves

Marimed

13/05/2026 22:08

Overview

U.S. cannabis operator's Q1 revenue rose 4% yr/yr to $39.5 mln

Adjusted EBITDA increased to $3.6 mln from $2.5 mln a year earlier

Company restructured Series B preferred stock, extending maturity and enhancing liquidity

Outlook

Company did not provide specific financial guidance for future quarters or the full year

Result Drivers

WHOLESALE AND RETAIL GROWTH - Co said revenue growth was supported by expanded wholesale distribution and retail growth

BRAND EXECUTION - Co said continued execution of its Expand the Brand strategy contributed to results

OPERATIONAL DISCIPLINE - Co cited disciplined operational execution and focus on efficiency and liquidity

Company press release: ID:nGNX7Zy5qR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$39.50 mln
$38.75 mln (2 Analysts)
Q1 Adjusted Net Income
Beat
-$3.20 mln
-$3.73 mln (2 Analysts)
Q1 Net Income
-$3.80 mln
Q1 Adjusted EBITDA
Miss
$3.60 mln
$4 mln (1 Analyst)
Q1 Gross Margin
39%
Q1 Adjusted EBITDA Margin
9%
Q1 Adjusted Gross Margin
40%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy"

Wall Street's median 12-month price target for MariMed Inc is $0.17, about 98.8% above its May 12 closing price of $0.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)